 The proposed research is designed to determine the cause and effect relationship between inflammation and CNS glutamate as well as the relationship between CNS glutamate and specific symptoms. To accomplish these aims, investigators will administer a single infusion of either the tumor necrosis factor TNF antagonist infliximab or placebo n30 per group to patients with high inflammation CRP3mgL. A CRP3mgL was chosen because it is considered high inflammation according to guidelines by the American Heart Association. Moreover, a CRP3mgL is associated with significantly increased basal ganglia glutamate and with a clinical response to infliximab. Inflammatory biomarkers, basal ganglia glutamate as measured by MRS, and motivation and psychomotor activity will be assessed at baseline and days 1 and 3 and weeks 1 and 2 following infliximab or placebo administration. 